Goldman Sachs analysts added ResMed (RMD) to the firm’s APAC Conviction List as part of its monthly update. The firm expects “robust” continuous airway pressure therapy patient growth assisted by growing awareness on obstructive sleep apnea.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- ResMed Reports Robust Growth and Innovation in Earnings Call
- Apple, Intel little changed near noon following earnings: Morning Buzz
- Zillow initiated, Electronic Arts upgraded: Wall Street’s top analyst calls
- ResMed upgraded to Buy at UBS as risks skew positive, consensus too cautious
- ResMed price target raised to $247 from $238 at RBC Capital